The prediction was also comprehensively validated by several independent benchmark gene sets, including 6 CRISPR gene sets associated with tumor resistance to cytotoxic T cells and targets of the 36 compounds that have been tested in clinical trials for combination treatments with anti-PD1. This evidence concerns the gene PDCD1 and neoplasm.